Weight Loss
Weight Loss
Weight Loss Management
GLP-1 and GIP/GLP-1 receptor agonists represent cutting-edge medications that have shown considerable advantages in the treatment of type 2 diabetes and weight management. GLP-1 receptor agonists work by stimulating insulin release, reducing blood sugar levels, and promoting weight loss, all while decreasing the risk of cardiovascular events. With a once-weekly dosing schedule, these medications improve patient compliance and convenience.
In contrast, GIP/GLP-1 receptor agonists leverage the advantages of both pathways, providing comprehensive blood sugar management and significant weight loss benefits. Research suggests that these dual-acting medications not only regulate glucose levels but also aid in sustainable weight reduction, making them a promising option for individuals managing both obesity and diabetes. These advancements in metabolic health treatments offer a multifaceted approach to improving patient outcomes and overall well-being.
Semaglutide is a medication belonging to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is used for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity or overweight who have at least one weight-related comorbidity.
Tirzepatide is a medication belonging to the class of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is currently being investigated for the treatment of type 2 diabetes mellitus and obesity.
Benefits
Benefits of GLP-1 and GIP/GLP-1 Receptor Agonists
GLP-1 and GIP/GLP-1 receptor agonists have demonstrated remarkable efficacy in lowering blood sugar levels in individuals with type 2 diabetes. By stimulating insulin release and inhibiting glucagon production, these medications help regulate blood glucose levels, leading to improved glycemic control.
Both GLP-1 and GIP/GLP-1 receptor agonists are associated with significant weight loss. Their mechanism of action includes delaying gastric emptying, promoting satiety, and reducing appetite, which can contribute to effective weight management for individuals with obesity or overweight conditions.
Studies have indicated that GLP-1 and GIP/GLP-1 receptor agonists may lower the risk of cardiovascular events, such as heart attacks and strokes, in patients with type 2 diabetes. This added cardiovascular benefit enhances the overall positive impact of these treatments on long-term health outcomes.
These medications are available in a convenient once-weekly dosing regimen, improving patient adherence and making treatment more manageable compared to medications requiring daily administration.
By effectively managing blood sugar levels, promoting weight loss, and reducing cardiovascular risks, GLP-1 and GIP/GLP-1 receptor agonists contribute to a better quality of life, allowing individuals to lead healthier, more active lifestyles.
GIP/GLP-1 receptor agonists combine the benefits of both pathways, offering a comprehensive and holistic approach to metabolic health management. By addressing multiple factors that contribute to diabetes and weight gain, they provide enhanced patient outcomes compared to traditional treatments.
Additional Benefits
Beyond the primary benefits, both GLP-1 and GIP/GLP-1 receptor agonists have demonstrated additional positive effects in clinical studies:
$100
- 45 minute virtual consultation includes complete medical examination and personalized nutrition plan.
- *Labs must be done prior to starting this medication- labs will be ordered or you can bring a recent result (within three months).
- Labs required withing 6 months.
$375 / for the first 4-6 weeks.
- Semaglutide once weekly injection of 0.25 mg x 4 weeks and 0.5 mg x 2 weeks.
- Personalized Consultation and Plan.
- Nutritional Counseling and Exercise Plan.
- Access to your provider via portal.
- Weekly check ins and accountability.
- 3 month package Sematiglutide ($1000)
$599 / for the first month.
- Tirzepatide once a week injection of 2.5 mg x 4weeks.
- Personalized Consultation and Plan.
- Nutritional Counseling and Exercise Plan.
- Access to your provider via portal.
- Weekly check ins and accountability.
GLP-1 Receptor Agonists
Some studies suggest that GLP-1 receptor agonists may help reduce the risk of kidney-related complications in individuals with type 2 diabetes.
Emerging research indicates potential cognitive benefits, suggesting that GLP-1 receptor agonists may play a role in supporting brain health.
GIP/GLP-1 Receptor Agonists
These medications have been linked to better cholesterol levels, which can contribute to improved cardiovascular health.
Studies indicate that GIP/GLP-1 receptor agonists may help lower liver fat content, making them beneficial for individuals with non-alcoholic fatty liver disease (NAFLD).
